Inflarx N V (IFRX) Stock
Small biotech developing treatments for inflammatory diseases. Here's the price, business snapshot, and what's worth knowing about Inflarx N V in October 2026.
InflaRx NV (IFRX) is a clinical-stage biotechnology company developing targeted therapies that modulate the complement system, principally a C5a‑directed monoclonal antibody. The firm focuses on inflammatory and immune‑mediated conditions where excessive complement activation is implicated. As a small‑cap, research‑heavy company with a market capitalisation around $92M, InflaRx’s value is closely tied to clinical trial outcomes, regulatory decisions and financing capacity. Investors should be aware of the high technical and regulatory risks inherent to drug development: early clinical success does not guarantee regulatory approval or commercial viability. Liquidity can be limited and share price volatility significant. This summary is educational and not investment advice; suitability depends on an investor’s objectives, time horizon and risk tolerance. Always consider reading company filings, monitoring trial updates and consulting a regulated financial adviser before making investment decisions.
Inflarx N V (IFRX) Stock Forecast
Analyst price target, next 12 months
$7.82
+401.2% vs today's $1.56
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Inflarx N V have a consensus 12-month target of $7.82, above the current price of $1.56.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying INFLARX N V stock with a target price of $7.82, indicating strong growth potential.
Financial Health
INFLARX N V has very low revenue despite a high gross margin, indicating potential challenges.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical-stage focus
Progress and value depend heavily on trial outcomes and regulatory milestones; this creates opportunity but also significant binary risk.
Pipeline-driven moves
Share performance tends to follow study readouts and approvals, so updates can cause sharp moves; diversification helps manage this volatility.
Market and funding
As a small-cap biotech, financing and partnerships matter for execution; funding gaps or delays can materially affect development timelines.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.